Next Phase Newsletter

A private investment firm funded by a single LP based in the Western United States invests in seed and early-stage health technology companies. The typical investment size for seed investment ranges from $250K to $1M (usually in equity or convertible notes). For early-stage companies, the firm typically co-invests with other VC firms in Series A and B financing and the investment size will depend on the company’s financial needs. The firm is geographically agnostic but prefers start-ups to be based on the West Coast. The firm is actively seeking new investment opportunities.

The firm has a focus on the digital health and informatics space, but also invests in novel therapeutics. Generally, the firm focuses on opportunities that avoid or mitigate FDA regulatory risks. The firm is agnostic in terms of subsectors and indications, but does not consider orphan indications. The firm will only consider technologies with proof of concept. Historically, the firm has invested in therapeutics that address oncology, infectious diseases, cardiovascular, and metabolic disorders; drug delivery; orthopedic devices; genomics.

The firm prefers to take a board seat but is generally flexible.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An approximately 200 million USD China based venture capital firm currently invests in healthcare (Pharmaceutical, medical device, diagnostics and Health IT) companies exclusively in China. In addition to investing in Chinese companies the firm is actively involved in and seeking to make new partnerships with technologies from around the globe in a number of specific technology areas exclusively for the Chinese market.

On the pharmaceutical end, the firm targets late stage assets post phase IIb to marketed products. For Medical technology products the firm currently holds companies that are looking for orthopedic products (spinal motion preservation and other non-fusion technologies), women’s health medical products, surgical instruments, dental devices and cardiovascular medical devices. On diagnostics, the primary focus is on oncology next generation sequencing systems and reagents; lastly for Health IT, diabetes management hardware.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A virtual pharma company founded in 2010 is currently seeking to in-license assets in the oncology sector, and is open to partnering with companies worldwide. The firm uses a wide variety of partnership structures, depending on the stage of development of the asset in question. The firm assesses therapeutic opportunities regularly and makes a new intake of assets every 1-2 years. The firm is open to working with companies worldwide, but generally focuses on North America and Europe-based opportunities.

The firm is interested in oncology therapeutics with novel mechanisms of action, and is open to working with small molecules and biologics, but not cell therapies. The firm seeks assets at any stage of development, from early preclinical development onward. The firm may also consider partnering with companies developing biomarker diagnostic technologies that guide cancer care decisions. In addition to standalone assets, the firm is interested in potential combinations of oncology treatments in areas such as immuno-oncology, checkpoint inhibitors, and other types of agents with combination potential. The firm will consider opportunities in all cancers, including orphan cancers; the firm’s portfolio currently includes ovarian and breast cancer assets, but other areas of cancer will also be considered, including liquid tumors. The firm is not currently interested in supportive care.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture arm of a large pharmaceutical company is mandated to invest directly in private early-stage life science companies with promising new products that may be future pipeline candidates. The firm seeks to invest across the more expansive business footprint of its parent company. The firm has a global mandate and is currently seeking new equity investment opportunities.

The firm is particularly interested in therapies for rare diseases, oncology, vaccines, and immune mediated diseases. The firm will also invest in breakthrough product candidates in other therapeutic areas such as cardiovascular and diabetes. The firm seeks products that are in preclinical or early clinical development and that have proof-of-concept data. The firm also willing to consider medical devices targeting these indications.

The firm generally co-invests with top tier life science investors and looks to take a minority position (<20%) in each portfolio company. The firm seeks to be a long-term investor with board responsibilities either as a full seat or as an observer.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com